Gene therapy startup Immusoft raises $3M, appoints new CEO as it approaches clinical trials

Sean Ainsworth joins Immusoft as its new CEO. (Immusoft Photo)

Immusoft is looking to get its gene therapy technology into clinical trials, and the Seattle startup announced Friday that it has raised $3 million to kickstart that process. The funding is first part of the company’s ongoing Series B round.

Immusoft also announced a leadership change: Veteran biotech executive Sean Ainsworth is joining the company as its new CEO, filling the shoes of the company’s Founder and longtime CEO Matthew Scholz. Scholz is transitioning to become the company’s CTO and will retain his position on the board of directors.

The $3 million round was led by the 600 Mile Challenge Fund,…